Should patients positive for HIV infection receive pneumococcal vaccine?
Pneumococcal vaccination effectively reduces the incidence of invasive pneumococcal disease in normal subjects. Such invasive pneumococcal disease is 100 times more common in patients with HIV infection than in healthy people, so it seems logical to target this group of patients for vaccination. Few clinics routinely vaccinate patients positive for HIV, despite Department of Health guidelines. This is because of uncertainty about the vaccine's efficacy in HIV disease. There are many reasons to suspect that the vaccine will fail to protect these patients, including the fact that antibodies alone may not be sufficient protection against all serogroups of Pneumococcus and the vaccine works in healthy people but not immunocompromised subjects. Vaccination of HIV positive patients may not be indicated, at least for the time being. The cost of vaccinating such patients in the absence of data showing efficacy may well be less than the cost of a necessarily large and lengthy trial. But the truth must be sought to end current indecision.
Jain
A
A
United Medical School of Guy's Hospital, London.
Jain
S
S
Gant
V
V
D017088:AIDS-Related Opportunistic Infections / Q000276:immunology / Q000517:prevention & control*; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001428:Bacterial Vaccines / Q000276:immunology*; D006679:HIV Seropositivity / Q000276:immunology*; D006801:Humans; D011008:Pneumococcal Infections / Q000276:immunology / Q000517:prevention & control*; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014611:Vaccination
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines